Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-to-head comparison

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 592-600

  Caroli, Anna ^a,b   Prestia, Annapaola ^a   Chen, Kewei ^c   Ayutyanont, Napatkamon ^c   Landau, Susan M ^d   Madison, Cindee M ^d   Haense, Cathleen ^e   Herholz, Karl ^f   Nobili, Flavio ^g   Reiman, Eric M ^c   Jagust, William J ^d   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer disease; Diagnostic performance; FDG PET summary metrics; Hypometabolism

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPOMETABOLIC CONVERGENCE INDEX; HYPOMETABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISCRIMINANT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84859406520     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094946     Document Type: Article

References (28)

1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746. (Pubitemid 47058377)
2. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
3. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
4. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
6. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67-77.
7. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131-144.
8. Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 2011;7:171-174.
9. Verwey NA, van der Flier WM, Blennow K, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem. 2009;46:235-240.
10. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94. (Pubitemid 27304784)
11. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
12. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-877. (Pubitemid 47329586)
13. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510. (Pubitemid 40591181)
14. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728-1733. (Pubitemid 41626670)
15. Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG-PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord. 2009;28:259-266.
16. Chen K, Ayutyanont N, Langbaum JBS, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011;56:52-60.
17. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207-1218.
18. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221-229.
19. Herholz K. PET studies in dementia. Ann Nucl Med. 2003;17:79-89. (Pubitemid 36693059)
20. Morbelli S, Drzezga A, Perneczky R, et al. Resting-state brain metabolic connectivity in amnestic MCI-AD converters and healthy controls: a joint project of the European Alzheimer's Disease Consortium (EADC). Eur J Nucl Med Mol Imaging. 2010;37(suppl 2):S259-S260.
21. Boccardi M, Laakso MP, Bresciani L, et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol Aging. 2003;24:95-103. (Pubitemid 35454147)
22. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786-794. (Pubitemid 27428023)
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
24. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
25. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992. (Pubitemid 33143977)
26. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193-1199.
27. 18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage. 1999;9:63-80.
28. Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.